Completion Pneumonectomy for Non-Small-Cell Lung Cancer: Does Induction Treatment Influence Postoperative Outcomes?
chemotherapy
lung cancer surgery
pneumonectomy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Jul 2022
13 Jul 2022
Historique:
received:
09
05
2022
revised:
04
07
2022
accepted:
11
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Completion pneumonectomy (CP) is associated with high morbidity and mortality. We reviewed our experience to evaluate whether induction treatment (IT) may affect postoperative outcomes and analyzed factors influencing long-term results. Between 1998 and 2020, 69 patients with lung cancer underwent CP (50 males, median age 63 years, right CP in 47 patients). A total of 23 patients (33.3%) received IT (chemotherapy in 15, chemoradiotherapy in 7, and radiation in 1). Surgery included 25 (36.2%) extended resections and five (7.2%) tracheal sleeve CP. The 30-day mortality rate was 7.2% (5/69), and overall morbidity was 37.6%. Major complications occurred in five patients (7.2%): one cardiac dislocation, one diaphragmatic hernia, one transient ischemic attack (TIA), and two bronchopleural fistulas. Minor complications occurred in 21 cases (30.4%): pulmonary in 12, cardiac in 7, and neurological in 2. The median hospital stay was 8 days (range, 5-56 days). IT did not influence postoperative morbidity and mortality. Pathological staging included 19 (27.5%) stage I, 36 (52.2%) stage II, and 14 (20.3%) stage III. Overall 5-year survival was 51.7%. Factors influencing survival were IT ( In our experience, CP had a low mortality, acceptable morbidity, and good long-term survival, which justifies this surgical procedure. Postoperative complications were not influenced by IT. Long-term survival was adversely influenced by the absence of IT, the presence of extended resection, the presence of squamous cell carcinoma, and cancers at advanced stages.
Sections du résumé
BACKGROUND
BACKGROUND
Completion pneumonectomy (CP) is associated with high morbidity and mortality. We reviewed our experience to evaluate whether induction treatment (IT) may affect postoperative outcomes and analyzed factors influencing long-term results.
METHODS
METHODS
Between 1998 and 2020, 69 patients with lung cancer underwent CP (50 males, median age 63 years, right CP in 47 patients). A total of 23 patients (33.3%) received IT (chemotherapy in 15, chemoradiotherapy in 7, and radiation in 1). Surgery included 25 (36.2%) extended resections and five (7.2%) tracheal sleeve CP.
RESULTS
RESULTS
The 30-day mortality rate was 7.2% (5/69), and overall morbidity was 37.6%. Major complications occurred in five patients (7.2%): one cardiac dislocation, one diaphragmatic hernia, one transient ischemic attack (TIA), and two bronchopleural fistulas. Minor complications occurred in 21 cases (30.4%): pulmonary in 12, cardiac in 7, and neurological in 2. The median hospital stay was 8 days (range, 5-56 days). IT did not influence postoperative morbidity and mortality. Pathological staging included 19 (27.5%) stage I, 36 (52.2%) stage II, and 14 (20.3%) stage III. Overall 5-year survival was 51.7%. Factors influencing survival were IT (
CONCLUSIONS
CONCLUSIONS
In our experience, CP had a low mortality, acceptable morbidity, and good long-term survival, which justifies this surgical procedure. Postoperative complications were not influenced by IT. Long-term survival was adversely influenced by the absence of IT, the presence of extended resection, the presence of squamous cell carcinoma, and cancers at advanced stages.
Identifiants
pubmed: 35884468
pii: cancers14143408
doi: 10.3390/cancers14143408
pmc: PMC9317965
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Future Oncol. 2020 Jun;16(16s):45-53
pubmed: 31912750
Eur J Cardiothorac Surg. 2012 Sep;42(3):405-9
pubmed: 22398467
Eur J Cardiothorac Surg. 1996;10(6):397-402
pubmed: 8817132
Ann Thorac Surg. 2002 Sep;74(3):876-83; discussion 883-4
pubmed: 12238854
Cancer. 2008 Mar 1;112(5):1106-13
pubmed: 18286507
J Thorac Oncol. 2012 Oct;7(10):1556-62
pubmed: 22982656
Acta Chir Belg. 2019 Oct;119(5):303-308
pubmed: 30821655
Eur J Cardiothorac Surg. 2008 May;33(5):837-43
pubmed: 18342530
J Cardiothorac Surg. 2012 Oct 09;7:107
pubmed: 23046489
Eur Respir J. 2005 Aug;26(2):192-7
pubmed: 16055865
Semin Respir Crit Care Med. 2008 Jun;29(3):302-17
pubmed: 18506668
J Clin Oncol. 2005 Sep 1;23(25):5910-7
pubmed: 16087956
Cancer. 2009 Sep 15;115(18):4156-66
pubmed: 19551884
Chest Surg Clin N Am. 1999 May;9(2):393-405, xi
pubmed: 10365271
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Am J Otolaryngol. 1998 Jan-Feb;19(1):18-23
pubmed: 9470946
Eur J Cardiothorac Surg. 2002 Jul;22(1):30-4
pubmed: 12103369
Ann Thorac Surg. 2000 Dec;70(6):1826-31
pubmed: 11156079
Ann Thorac Cardiovasc Surg. 2011;17(1):24-8
pubmed: 21587124
J Thorac Cardiovasc Surg. 2001 Mar;121(3):484-90
pubmed: 11241083
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
Interact Cardiovasc Thorac Surg. 2014 Sep;19(3):436-40
pubmed: 24893868
Lancet. 2007 Jun 9;369(9577):1929-37
pubmed: 17544497
J Thorac Cardiovasc Surg. 1975 Oct;70(4):606-12
pubmed: 170482
J Thorac Cardiovasc Surg. 1999 Jun;117(6):1095-101
pubmed: 10343257
Eur J Cardiothorac Surg. 2004 Mar;25(3):449-55
pubmed: 15019677
Ann Thorac Surg. 1988 Aug;46(2):141-6
pubmed: 3401074
J Thorac Dis. 2020 Mar;12(3):217-222
pubmed: 32274087
J Thorac Cardiovasc Surg. 2006 Sep;132(3):519-23
pubmed: 16935104
World J Surg Oncol. 2018 May 28;16(1):98
pubmed: 29807542
Eur Respir J. 2016 Feb;47(2):374-8
pubmed: 26828046
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
J Thorac Cardiovasc Surg. 2001 Apr;121(4):642-8
pubmed: 11279403
J Clin Oncol. 1995 Aug;13(8):1880-92
pubmed: 7636530
J Thorac Cardiovasc Surg. 2001 Jun;121(6):1076-82
pubmed: 11385374
J Thorac Cardiovasc Surg. 1993 May;105(5):918-24
pubmed: 8487570